Whitehawk Therapeutics Inc. (WHWK)
WHWK trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1422142/000119312526104158/0001193125-26-104158-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | WHWK on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001422142 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $7.1M |
| Net income | -$20.6M |
| Operating income | -$114.4M |
| Net margin | -288.3% |
| Operating margin | -1601.1% |
| Revenue growth | -72.5% |
| Cash | $37.6M |
| Total assets | $150.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 24.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $69.0M cash; operating cash flow -$18.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 59,008,982 (2026-11-05); 47,128,362 a year earlier; 24,525,860 three years earlier. | Cover page 2026-11-05 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-05-29 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BDO USA, P.C., San Diego, California, United States | PCAOB Form AP 2026-03-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $2.6M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$21.2M | -$19.7M | $69.0M | No debt tags | $0 | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $0 | -$16.6M | -$14.5M | $85.2M | No debt tags | $0 | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $0 | -$22.2M | -$22.2M | $34.8M | No debt tags | $0 | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $0 | -$23.3M | -$17.2M | $37.6M | No debt tags | $7.1M | 10-K 2026-03-12 |
| Q3 2025 2025-09-30 | $0 | -$17.7M | -$15.4M | $37.9M | No debt tags | $14.4M | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $0 | -$52.6M | -$53.0M | $144.9M | No debt tags | $21.6M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $7.1M | $73.0M | -$11.9M | $227.6M | No debt tags | $27.8M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $7.2M | -$18.3M | -$15.1M | $28.7M | No debt tags | $26.0M | 10-K 2026-03-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-05-29 |
| Latest annual report | 10-K | 2026-03-12 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 676 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.2% |
| 1 month | +1.3% |
| 3 months | -34.6% |
| Year to date | +26.4% |
| 1 year | +46.4% |
| From 52-week high | -40.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SLGL | Sol-Gel Technologies Ltd. | $54.96 | -0.29% | $179.9M |
| KRRO | Korro Bio Inc. | $12.71 | -6.61% | $174.5M |
| IFRX | InflaRx N.V. | $1.18 | +0.85% | $173.9M |
| NATR | Nature's Sunshine Products Inc. | $10.56 | +1.93% | $183.0M |
| RNAC | Cartesian Therapeutics Inc. | $6.08 | -4.25% | $185.5M |
| ANTX | AN2 Therapeutics Inc. | $4.47 | -1.76% | $169.6M |
| ORMP | Oramed Pharmaceuticals Inc. | $3.90 | +5.12% | $169.6M |
| PYXS | Pyxis Oncology Inc. | $1.41 | -10.76% | $168.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier